We modified an existing enzyme-linked immunosorbent assay (ELISA) to be able to use new spectrophotometers which can measure the rate of color development in microtiter wells. This new kinetic-based ELISA (KELISA) required only a single dilution of specimen rather than the multiple dilutions required with endpoint ELISA. In addition, 10-to 100-fold-less specimen was required-to perform the KELISA than the ELISA. The level of sérum or nasal wash antibody against surface glycoproteins of influenza A or influenza B viruses determined by KELISA was reproducible and correlated highly with the results of endpoint ELISA or hemagglutination inhibition tests. The difference between the KELISA rates, which indicated than an antibody response to infection had occurred, was defined and was analogous to a 2.2-fold rise in titer for serum and a 3.4-fold rise in titer for nasal wash determined by endpoint ELISA. The KELISA was similar to endpoint ELISAs in its ability to detect rises in antibody level in paired serum or nasal wash specimens obtained from volunteers who received live attenuated influenza A reassortant virus vaccines. By eliminating the need for multiple dilutions, the use of KELISA offers the advantage of increasing the number of assays that can be performed by the same personnel compared with endpoint ELISA, while it maintains sensitivity and specificity.
Enzyme-linked immunosorbent assay (ELISA) provides a sensitive solid-phase system for the detection of antibody of using microvolume samples (2, (4) (5) (6) 8) . Modifications of ELISAs have been developed to assay for immunoglobulin class-or subclass-specific rises in antibody titer against specific antigens (11, 19, 21) . Results of endpoint ELISAs are reported as the last dilution of specimen which produces a specified level of optical density (OD) in a set incubation time after the addition of substrate. ODs must be read at a specified time because the OD in any given well rises linearly and then reaches a plateau. The dynamic range of the endpoint ELISA is limited to those dilutions which produce reactions which are still in the linear phase of color development when the readings are performed. A recently developed modification of the ELISA, kinetic-based ELISA (KELISA), measures the rate of color development during the early portion of the development reaction (18) . The rate of color development is proportional to the amount of conjugated antibody bound on the solid phase. Thus, both the KELISA and endpoint ELISA measure the amount of conjugated antibody bound in the assay. Since the readings are made soon after substrate addition, the dynamic range of KELISA is not limited by the reaction reaching the plateau phase.
Other investigators have reported previously that the extended dynamic range of KELISA eliminates the need to perform serial dilutions of serum to determine the quantity of antibody present (1, 3, 9, (14) (15) (16) (17) 20) . In our studies, we were interested in analyzing paired pre-and postinfection serum or nasal wash specimens for evidence of an immune response to live attenuated influenza virus vaccines as well as for the quantity of antibody present in the postimmunization specimens. We modified our endpoint ELISA to provide kinetic-based determinations of immunoglobulin class-spe-* Corresponding author. cific antibody levels by using a single dilution of serum or nasal wash. In addition, we determined the differences in KELISA rates of pre-and postinfection serum or nasal wash specimens that constituted a significant antibody response. Results obtained with the KELISA were reproducible and correlated with those of endpoint ELISA and hemagglutination inhibition (HAI) tests. Serum and nasal wash specimens from two vaccine trials were analyzed by KELISA, and the results were compared with those obtained by endpoint ELISA or HAI. We found that KELISA performed with a single dilution was as sensitive and specific as the other tests which require multiple dilutions. (7) which contained the HA and neuraminidase (HANA) of the A/Texas/1/85 virus was used as antigen in the ELISA and KELISA. Because we lacked sufficient quantities of purified HA of the A/Mississippi/l/85 virus to complete these studies, purified HA of the A/Bethesda/l/85 virus was prepared as described previously (13) and used as antigen in the KELISA. The results of endpoint ELISA or KELISA performed with these two antigens were similar.
MATERIALS AND METHODS

Serum
ELISA and KELISA. Endpoint ELISAs were performed as described previously (11) . Briefly, the ladder of reagents consisted of HA or HANA, which was adsorbed onto the plate in carbonate buffer, followed by the serum or nasal wash specimen, immunoglobulin class-specific rabbit antihuman immunoglobulin G (IgG) (for serum) or IgA (for nasal wash specimens) antibody, and goat anti-rabbit IgG antibody conjugated with alkaline phosphatase. After the addition of p-nitrophenol phosphate substrate, the plates were incubated at 37°C for 60 min. The tests were then read in a multichannel spectrophotometer. The endpoint ELISA titers were determined as the highest dilution which gave an OD of >0.20 OD units and whose OD was twice that of background, as defined previously (11 
RESULTS
Determination of optimal dilution of conjugate and serum. In order to convert our endpoint ELISA system to a KELISA, it was necessary to identify dilutions of serum or nasal wash and of conjugated antibody such that the amount of antibody bound directly to the solid-phase antigen was the limiting reagent in the assay. For this determination we performed a checkerboard titration in which various combinations of specimen dilutions and conjugate dilutions were evaluated. The dilution of immunoglobulin class-specific rabbit anti-human IgG antibody used as a second (intermediate) antibody was the same in both the endpoint ELISA and KELISA. The relationship between the KELISA rate, the dilution of serum, and the amount of goat anti-rabbit alkaline phosphatase conjugate used is presented in Fig. 1 16 -fold greater than that used in the endpoint ELISA. The log10 of the KELISA rate was linearly related to the quantity of antibody for serum dilutions in the range of 1: 2,000 to 1:645,000. Based on this and similar results with other high-titer specimens (data not shown), we chose 1: 4,000 as the single dilution at which adult serum specimens would be used in the KELISA. Thus, a linear relationship between the log1o KELISA rate and the log2 antibody titer would be obtained for specimens whose endpoint ELISA HA-specific IgG antibody titers were in the range of 1:1,000 to 1:320,000. This range encompasses almost the entire range of ELISA HA-specific IgG antibody titers in serum that are commonly seen in young adults who participate in our studies of live attenuated influenza A virus vaccines. We performed similar studies (data not shown) using nasal washes which were obtained from young adults and concentrated 10-fold as described previously (10), and found that 1: 64 was the optimal dilution of nasal wash for use in the KELISA. Because the antibody titers of truly seronegative infants and children are lower than the lowest titers seen in young adults, all of whom were infected previously with influenza A viruses, we chose 1:560 as the dilution at which serum specimens from such infants and children would be analyzed.
A limiting factor in many ELISAs is the nonspecific binding of antibody to the plate. Typically, in our endpoint ELISA, very little background was present when 1:4,000 dilutions of serum or 1:64 dilutions of nasal wash were analyzed. To determine whether the background contributed significantly to the KELISA values obtained under the conditions specified above, specimens were analyzed in duplicate wells on microtiter plates. One well was precoated previously with HA antigen; the other was not precoated. The 10% of the rate for the corresponding well which contained antigen (data not shown). Similar low background rates were also observed when sera from children were analyzed at a 1: 560 dilution. Thus, nonspecific background made a negligible contribution to the KELISA rates.
Correlation of KELISA with endpoint ELISA and HAI. We measured the amount of HAI antibody or IgG antibody against the HA or HANA of influenza A H3N2 or HlNi virus, as detected by the endpoint ELISA or KELISAs, using serum specimens obtained from infants, children, and adults who were screened for eligibility to participate in our vaccine trials. We found a high correlation among the three assays in adults (Spearman rank correlation coefficient [r5], 0.61 to 0.72; P < 10-6) ( Fig. 2 and 3 ) and in infants and children (r5, 0.81 to 0.92; P < 0.001) (data not shown). Similarly, the KELISA rate correlated with the rates of the HAI and endpoint ELISA for influenza B virus antigens (data not presented). For nasal wash specimens, the IgA levels against surface glycoprotein from influenza A H3N2, influenza A HlNi, or influenza B viruses, as determined by KELISA, also correlated with the levels determined by endpoint ELISA (data not shown). KELISA to identify antibody responses. To utilize the KELISA to evaluate paired serum or nasal wash specimens for evidence of an antigen-specific antibody response, it was necessary to define a minimum difference between KELISA values which would signify an antibody response. The relationship between KELISA rate and antibody titer that we described above suggested that an appropriate criterion to discriminate between significant and insignificant changes in KELISA rates would be a fold rise in antibody level, as indicated by the ratio between the KELISA rates determined for pre-and postinfection specimens. To define such a ratio, we first needed to define the variability of KELISA rates for a single specimen when replicate assays were performed on the same microtiter plate. This analysis of well-to-well variability within a microtiter plate would be applicable to a typical assay situation in which the paired pre-and postinfection specimens are assayed in adjacent wells. Forty-eight serum samples were assayed in quadruplicate, and the results of replicate assays were compared in a pairwise manner. The ratio of each pair of KELISA rates was determined, and the frequency with which these ratios exceeded various predetermined ratios is shown in Table 1 . A KELISA rate ratio of 1.8 or greater was seen in only 6% of the pairwise comparisons; therefore, this ratio was chosen as the minimum ratio that would indicate that an antibody response occurred between the times of collection of the preand postinfection specimens. Similar assays were performed by using nasal wash specimens. The variability of the nasal wash data was greater than that of the serum data, and a similar analysis yielded a ratio of 2.9 for use in identifying antibody responses in nasal wash specimens.
It is possible to apply these ratios to data obtained from a serially diluted sample, such as is shown in Fig. 1 (12) .
Analysis of the mean pre-and postvaccination antibody levels shown in Table 4 indicates that the group mean KELISA rate provides information similar to the mean endpoint ELISA titer. There was a correspondence between the endpoint ELISA and KELISA in the relative magnitude of the rise in mean antibody level between the pre-and postinfection specimens. However, the mean endpoint ELISA antibody titer in serum of vaccinees who received 104i-TCID50s of A/Bethesda/1/85 virus vaccine unexpectedly declined during the 3-week period. This demonstrates that the results of discontinuous assays such as endpoint ELISA can be distorted by a few cases in which a preinfection specimen just exceeds but the postinfection specimens falls short of the cutoff for assignment to a higher titer. In contrast, the KELISA rate is numerically continuous; it more accurately reflects the small rise in mean antibody level that one would expect in volunteers who received a small fraction of the 50% human infectious dose of vaccine virus (Sears et al., submitted). Test-to-test reproducibility. We next sought to determine the reproducibility of KELISA rates from test to test. We found that factors similar to those which affect color development in the endpoint ELISA could also contribute to the variability in the KELISA. Among those factors were the duration of exposure of the conjugated enzyme to the detergent Tween 20 during washes and the pH of the buffer in which the substrate was dissolved (data not shown). Although most tests remained within a twofold range, we observed that the absolute magnitude of KELISA rates could vary as much as fourfold from test to test (data not shown). Despite the variability of the absolute magnitude of the KELISA rates, the relative order of KELISA rates belonging to various specimens remained similar from test to test. We found that if a control specimen was included on each plate, the values of test specimens could be transformed by the following formula: log RT = log Ri x logCJlog Ci, where RT is the transformed KELISA rate for a specimen; Ri is the rate for that specimen in a particular assay; Ci is the rate for the control specimen in the same assay; and C0 is an assigned value for the control specimen which might be based on the rate determined for the control specimen in an oe . initial KELISA. To test this method, we chose four tests in which a group of serum specimens obtained from community members, as described above, were analyzed. The KELISA rates obtained in each assay were transformed by the formula given above, and the transformed values are shown in Fig. 4 . In Fig. 4 the x-axis value, which represents the result of the first assay, is the same for each subsequent assay of that specimen. The symbols representing the second, third, and fourth assays for each specimen are aligned vertically.
The results in Fig. 4 and of the r, performed with the transformed data for the four different assays (r5, 0.82 to 0.91; P < 10-6) demonstrate that the KELISA reproducibly orders serum samples with various antibody levels. Furthermore, an analysis of variance with transformed data showed that specimen-to-specimen variability was 
